Avoro Capital Advisors 13F: Exits GLUE Stake

Avoro Capital Advisors has sold its entire stake in Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE). According to the latest 13F filing with the SEC, Avoro cut 3.73 million shares, leaving it with no holdings in the company as of the filing date.

What Changed in Avoro Capital Advisors' Monte Rosa Therapeutics Position

Avoro Capital Advisors completely exited its position in Monte Rosa Therapeutics, eliminating 3.73 million shares. The transaction reflects a 100% reduction from its previous holdings, marking a decisive move to sell out its stake.

Other Institutional Activity in Monte Rosa Therapeutics

In the same period, other institutional investors showed varied interest in Monte Rosa Therapeutics. NEA Management Company, LLC maintained its position with 7.69 million shares valued at approximately $126.5 million. Price T Rowe Associates Inc. increased its holdings by 1.60 million shares, bringing its total to 6.72 million shares worth about $110.5 million. Versant Venture Management, LLC added 1.98 million shares, ending with 6.36 million shares valued at $104.6 million. BlackRock, Inc. also expanded its position by 1.46 million shares, totaling 5.64 million shares valued at $92.7 million.

Monte Rosa Therapeutics, Inc. Stock Up 99.5%

Shares of Monte Rosa Therapeutics traded near $17.66. The company has a market cap of approximately $1.54 billion. It operates with a forward P/E ratio that isn't meaningful due to its lack of profitability. The stock's 52-week low is $4.12, and its high is $25.77. Monte Rosa's 50-day moving average is $18.59, and the 200-day moving average is $15.58. The company maintains a strong liquidity position with a current ratio of 9.54 and a quick ratio of 9.44, alongside a debt-to-equity ratio of 7.49.

Recent Earnings

Monte Rosa Therapeutics reported revenue of $42.95 million, although it experienced a revenue decline of 95%. The company posted a net margin of 0%, and its return on equity was -32.6%. The next earnings report is scheduled for May 7, 2026.

Insider Buying and Selling at Monte Rosa Therapeutics, Inc.

On June 11, 2026, several insiders bought shares of Monte Rosa Therapeutics. Eric Hughes, Christine Siu, Ali Behbahani, Anthony Manning, Andrew Schiff, and Kimberly Blackwell each purchased 25,800 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On May 11, 2026, JP Morgan maintained its 'buy' rating on Monte Rosa Therapeutics with a price target of $31. Guggenheim also kept its 'buy' rating, setting a target of $30 on March 18, 2026. Wells Fargo reiterated a 'buy' rating with a target of $29 on the same day. Overall, the consensus among analysts is a strong buy, with an average target price of $32.33 based on six analyst opinions.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing small molecule precision medicines that target and degrade specific proteins related to various diseases. The company's pipeline includes treatments for MYC-driven tumors, neurologic and autoimmune diseases, as well as inflammatory conditions. Monte Rosa collaborates with major pharmaceutical companies such as F. Hoffmann-La Roche and Novartis. Founded in 2019, the company is led by CEO Dr. Markus Warmuth and employs 187 people.

Bottom Line

Avoro Capital Advisors' decision to sell its entire stake in Monte Rosa Therapeutics is a notable development in the company's investor landscape. While 13F filings are backward-looking and may not reflect current positions, they offer insight into institutional sentiment. Monte Rosa continues to attract attention with its innovative approach to drug development and strong buy recommendations from analysts.